MATOKE LIMITED

Matoke Limited is a pioneering medical‑technology company dedicated to confronting the rising threat of antimicrobial resistance (AMR) in chronic wound care. By harnessing its proprietary Matoke Reactive Oxygen (RO) Technology, the firm delivers innovative therapeutic solutions that actively combat resistant pathogens while promoting healing.

The company’s core offering centres on RO‑based wound‑treatment products, engineered specifically to address AMR challenges and to provide clinicians with effective alternatives to traditional antimicrobial dressings. Matoke’s pipeline is expanding under the guidance of its newly appointed Chief Technology Officer, Neil Johnson, whose fifteen‑year background in medical devices and over‑the‑counter healthcare strengthens the development of multiple RO‑enabled products.

Matoke’s work has attracted attention from regulatory bodies, with recent FDA discussions on re‑classifying silver wound dressings highlighting the importance of novel, resistance‑focused technologies. Through its forward‑thinking approach, Matoke serves healthcare professionals seeking cutting‑edge, evidence‑based solutions for chronic wound management.